Dextech Medical FCF/Debt

What does Dextech Medical do? Dextech Medical AB is a biotechnology company based in Uppsala, Sweden, operating within the healthcare sector. The company has a single full-time employee and went public via an IPO on June 19, 2014. Its primary focus is the research and development of drug candidates targeting urological oncology, with specific emphasis on prostate cancer, as well as other cancers and non-malignant diseases. Dextech Medical AB utilizes a technology platform called GuaDex, which is patented, and has developed three drug candidates with associated patents or patent applications. These candidates include OsteoDex, designed for the treatment of bone metastases in castration-resistant prostate cancer; SomaDex, which leverages somatostatin, an endogenous hormone, for the treatment of acromegaly, neuroendocrine tumors, and palliative care for prostate cancer; and CatDex, intended for the instillation treatment of bladder cancer. The company's website is https://dextechmedical.com/. Dextech Medical AB is listed under the ticker DEX.SL with ISIN SE0005881489. The company's operations are centered around developing innovative therapeutic solutions through its proprietary platform, aiming to address significant unmet medical needs in oncology and related fields. Dextech Medical is one of the most popular companies on Eulerpool.